The Food and Drug Administration has agreed that the available efficacy and safety data for DBV Technologies' (Nasdaq: DBVT) Viaskin Peanut supports submission of a Biologics License Application for the treatment of peanut allergy in children four to 11 years of age. Shares of the biopharmaceutical leaped $5.37 to close at $26.23.
